Alterations in Spinal Cord Metabolism during Treatment of Neuropathic Pain
| Autor: | Caroline H. Johnson, Gary Siuzdak, Leah P. Shriver, Marianne Manchester, Linh Hoang, Gary J. Patti, Jean-Philippe Courade |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.drug_class Metabolite Immunology Central nervous system Pregabalin Neuroscience (miscellaneous) Oleic Acids Endogeny Pharmacology Antimetabolite Article Rats Sprague-Dawley chemistry.chemical_compound Sphingosine medicine Animals Metabolomics Immunology and Allergy Cannabinoid Receptor Agonists Analgesics business.industry Lipid metabolism Spinal cord Rats Disease Models Animal medicine.anatomical_structure Spinal Cord chemistry Ethanolamines Neuropathic pain Neuralgia business Endocannabinoids medicine.drug |
| Zdroj: | Journal of Neuroimmune Pharmacology. 10:396-401 |
| ISSN: | 1557-1904 1557-1890 |
| DOI: | 10.1007/s11481-015-9624-y |
| Popis: | Therapeutic options for neuropathic pain have improved over the last 20 years yet still only provide partial relief with numerous side effects. Recently, metabolomics revealed that the concentration of the endogenous metabolite N,N-dimethylsphingosine (DMS) is increased in the spinal cord in a model of neuropathic pain. Additionally, it was shown that introduction of DMS to the central nervous system (CNS) resulted in mechanical allodynia. Here, we have examined two compounds; pregabalin (Lyrica®), a drug used to treat neuropathic pain, and N-oleoylethanolamine (NOE), an endogenous endocannabinoid-like compound that is known to affect multiple lipid pathways. We found that the concentration of DMS in the spinal cord was not significantly altered upon pregabalin treatment of rats suffering from neuropathic pain. We further explored whether modulating lipid metabolism may impact neuropathic pain by testing NOE as a potential novel therapeutic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink